Background Although new individual treatments continue to reshape the landscape of
clinical care in patients with lung cancer, most of the progress has been mainly of benefit to …

Background The process of selecting patients on the basis of epidermal growth factor
receptor (EGFR) mutations would likely result in a patient population with greater sensitivity …

Objective Epidermal growth factor receptor (EGFR) mutation mostly occurred in lung
adenocarcinoma, rarely in squamous cell carcinoma (SQCC). EGFR mutation rate in SQCC …

Background Epidermal growth factor receptor (EGFR) mutations in lung carcinomas can
make the disease more responsive to the treatment with tyrosine kinase inhibitors. We …

Introduction: Epidermal growth factor receptor (EGFR) mutations are found mostly in
adenocarcinoma, and rarely in squamous cell carcinoma (SQC). Little is known about SQC …

Objective To investigate the frequency of epidermal growth factor receptor (EGFR) mutations
and their correlation with the efficacy of tyrosine kinase inhibitors (EGFR-TKI) in advanced …

Objective This study analyzed the relationship between the clinicopathological features and
epidermal growth factor receptor (EGFR) mutation status of squamous cell lung cancer …

Objective To explore the clinicopathological features associated with epidermal growth
factor receptor (EGFR) gene mutation in non-small cell lung cancer (NSCLC) patients …

Epidermal growth factor receptor (EGFR) gene mutations have been reported to be clinically
significant in non-small cell lung cancer (NSCLC). However, because most previous studies …

Objective. The aim of this study was to examine the prevalence of epidermal growth factor
receptor (EGFR) gene mutations among patients with advanced nonsquamous non–small …